Detailed Narrative
CONNECT Trial Demonstrates Significant Benefits for Type 2 Non-Insulin Patients
The CONNECT randomized controlled trial for people with type 2 diabetes not using insulin showed a 1.6% A1c improvement for the Dexcom CGM group, resulting in a 0.9% difference compared to the control group over a 6-month period. Participants spent over 5 more hours per day in normal glucose range, with improvements sustained over 26 weeks. Median CGM usage was notably high at 97%, and the largest relative A1c improvement was observed in the GLP-1 therapy cohort, reinforcing CGM's complementary role with incretin therapies.
Expanding Commercial Coverage and Evidence for Cost Savings
Dexcom has achieved coverage for all people with diabetes across the four largest commercial PBMs, extending reimbursement to over 7 million type 2 non-insulin individuals. A real-world evidence study with CVS Health demonstrated a 66% reduction in diabetes-related hospitalizations and nearly 50% reduction in microvascular complications after CGM initiation, highlighting tangible near-term cost savings that drive commercial coverage.
FDA TEMPO Pilot and Prediabetes Screening Initiative
Dexcom was selected as the first company to participate in the FDA's TEMPO digital device pilot, an innovative regulatory framework aimed at accelerating access to technology for early-stage cardiometabolic conditions. This program will allow Dexcom to demonstrate the ability of its CGM technology to screen for prediabetes and promote better metabolic health among the 115 million Americans with prediabetes, many of whom are unaware of their condition.
Product Innovation and Enhanced User Experience
The company launched a fully redesigned Stelo app, featuring a consumer-friendly interface, AI-driven insights, and enhanced food logging capabilities, which will also form the foundation for future G series app evolution. The pilot program for Dexcom Smart Basal, a personalized dosing module for basal insulin management, showed promising results, helping customers achieve optimal basal doses in an average of 3 weeks, significantly faster than the typical 12+ weeks.
G7 15-Day System Rollout and International Expansion
The Dexcom G7 15-day system is now accessible for all adult G7 customers in the U.S., including those using Tandem pumps, following recent integration availability. Customer satisfaction, measured by Net Promoter Scores, has increased for three consecutive quarters. Internationally, Health Canada cleared the G7 15 Day system, with a launch planned for the second half of 2026, and Dexcom Flex, a 15-day sensor for type 2 basal and non-insulin markets, was launched in Germany.
Strategic Capital Allocation and Nutrisense Acquisition
Dexcom announced a $1 billion share repurchase authorization for 2026, with approximately $600 million already executed in Q2. In line with its capital allocation framework, the company acquired Nutrisense, a platform built on CGM data that provides nutrition-focused insights. This acquisition aims to enhance customer experience and offer new personalized insights, with its revenue contribution being immaterial to the top line but significant for technology capabilities.